SEOUL -- An immunoglobulin drug based on plasma containing antibodies, developed by GC Pharma, a biotech company in South Korea, has been administered to COVID-19 patients in a second-stage clinical study involving 60 people to set proper dosage and check safety and efficacy.
GC Pharma said that it began administering its new drug called "GC5131A" over the weekend to COVID-19 patients who took part in Phase 2 clinical trials. The company has been involved in a state project to develop plasma treatment, which is different from plasma therapy involving the infusions of blood plasma from COVID-19 survivors. Third-sage clinical trials will be carried out abroad through an international alliance involving plasma companies.
South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. South Korea's public health watchdog has approved second and third-stage clinical trials to verify the efficacy and safety of Celltrion's antibody treatment, CT-P59, that showed safety and drug tolerance in the first-stage test involving healthy people in August.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.